agenT-797 Plus Standard Care for Severe Pneumonia With Respiratory Failure
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether adding an experimental drug called agenT-797 to standard pneumonia treatment helps patients in the ICU who have severe pneumonia and serious difficulty breathing (acute hypoxemic respiratory failure). The drug is designed to help the immune system fight severe infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be admitted to an ICU with severe pneumonia (caused by virus, bacteria, fungus, or a mix) and serious breathing problems
- You must have moderate to severe acute respiratory distress syndrome (ARDS)—a condition where fluid builds up in the lungs and makes it hard to get oxygen
- Your severe pneumonia and breathing problems started within the last 7 days
- You are not using more than 2 blood-pressure medications (vasopressors) to keep your blood pressure stable
- You are not pregnant, breastfeeding, or currently in another drug trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach combining a traditional Chinese medicine formula with bacteriophages (viruses that attack bacteria) to treat severe pneumonia caused by antibiotic-resistant bacteria. It aims to see if this combination can improve outcomes for patients who have limited treatment options.
This trial tests different treatments for serious lung infections in people who are already in the hospital. It may help doctors learn which treatment works best for recovery and survival when pneumonia-like illness is suspected.
This trial tests a new drug called SR1375 for adults with severe community-acquired pneumonia (a lung infection) who are not improving with standard antibiotics. It may help reduce inflammation and speed up recovery.
This trial tests a new medicine called GKL-006RTU for people with moderate to severe ARDS caused by an infection. The goal is to see if it is safe and helps improve breathing and recovery.
This study tests an experimental drug (STSA-1002) for people with severe breathing problems caused by a viral infection. It aims to see if the drug can help improve oxygen levels and reduce the need for a breathing machine.
This study tests ways to improve treatment for adults with severe pneumonia that lands them in the ICU, adjusting the plan as results come in. It may help your care team find better treatments for lung infection and breathing/heart support needs.
Hear when a new Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.